Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

269 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.
Yang G, Wang J, Tan L, Munshi M, Liu X, Kofides A, Chen JG, Tsakmaklis N, Demos MG, Guerrera ML, Xu L, Hunter ZR, Che J, Patterson CJ, Meid K, Castillo JJ, Munshi NC, Anderson KC, Cameron M, Buhrlage SJ, Gray NS, Treon SP. Yang G, et al. Among authors: munshi nc, munshi m. Blood. 2021 Nov 18;138(20):1966-1979. doi: 10.1182/blood.2021011405. Blood. 2021. PMID: 34132782 Free PMC article.
BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism.
Chen JG, Liu X, Munshi M, Xu L, Tsakmaklis N, Demos MG, Kofides A, Guerrera ML, Chan GG, Patterson CJ, Meid K, Gustine J, Dubeau T, Severns P, Castillo JJ, Hunter ZR, Wang J, Buhrlage SJ, Gray NS, Treon SP, Yang G. Chen JG, et al. Among authors: munshi m. Blood. 2018 May 3;131(18):2047-2059. doi: 10.1182/blood-2017-10-811752. Epub 2018 Mar 1. Blood. 2018. PMID: 29496671 Free article.
TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia.
Gustine JN, Tsakmaklis N, Demos MG, Kofides A, Chen JG, Liu X, Munshi M, Guerrera ML, Chan GG, Patterson CJ, Meid K, Dubeau T, Yang G, Hunter ZR, Treon SP, Castillo JJ, Xu L. Gustine JN, et al. Among authors: munshi m. Br J Haematol. 2019 Jan;184(2):242-245. doi: 10.1111/bjh.15560. Epub 2018 Sep 5. Br J Haematol. 2019. PMID: 30183082 Free article.
Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.
Hunter ZR, Xu L, Tsakmaklis N, Demos MG, Kofides A, Jimenez C, Chan GG, Chen J, Liu X, Munshi M, Gustine J, Meid K, Patterson CJ, Yang G, Dubeau T, Samur MK, Castillo JJ, Anderson KC, Munshi NC, Treon SP. Hunter ZR, et al. Among authors: munshi nc, munshi m. Blood Adv. 2018 Nov 13;2(21):2937-2946. doi: 10.1182/bloodadvances.2018022962. Blood Adv. 2018. PMID: 30401751 Free PMC article.
CXCR4S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia.
Gustine JN, Xu L, Tsakmaklis N, Demos MG, Kofides A, Chen JG, Liu X, Munshi M, Guerrera ML, Chan GG, Patterson CJ, Keezer A, Meid K, Dubeau T, Yang G, Hunter ZR, Treon SP, Castillo JJ. Gustine JN, et al. Among authors: munshi m. Blood Adv. 2019 Oct 8;3(19):2800-2803. doi: 10.1182/bloodadvances.2019000635. Blood Adv. 2019. PMID: 31570491 Free PMC article.
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas.
Munshi M, Liu X, Chen JG, Xu L, Tsakmaklis N, Demos MG, Kofides A, Guerrera ML, Jimenez C, Chan GG, Hunter ZR, Palomba ML, Argyropoulos KV, Meid K, Keezer A, Gustine J, Dubeau T, Castillo JJ, Patterson CJ, Wang J, Buhrlage SJ, Gray NS, Treon SP, Yang G. Munshi M, et al. Blood Cancer J. 2020 Jan 31;10(1):12. doi: 10.1038/s41408-020-0277-6. Blood Cancer J. 2020. PMID: 32005797 Free PMC article.
Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia.
Jiménez C, Chan GG, Xu L, Tsakmaklis N, Kofides A, Demos MG, Chen J, Liu X, Munshi M, Yang G, Castillo JJ, Wiestner A, García-Sanz R, Treon SP, Hunter ZR. Jiménez C, et al. Among authors: munshi m. Br J Haematol. 2020 Jun;189(6):1165-1170. doi: 10.1111/bjh.16463. Epub 2020 Feb 27. Br J Haematol. 2020. PMID: 32103491 Free PMC article. Clinical Trial.
Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up.
Castillo JJ, Meid K, Flynn CA, Chen J, Demos MG, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, Patterson CJ, Yang G, Hunter Z, Treon SP. Castillo JJ, et al. Among authors: munshi m. Blood Adv. 2020 Aug 25;4(16):3952-3959. doi: 10.1182/bloodadvances.2020001963. Blood Adv. 2020. PMID: 32822482 Free PMC article. Clinical Trial.
269 results